LabStat costs sank Community Health ComputingIt's not very often that ADAC Laboratories makes a misstep, but this month the Milpitas, CA, company acknowledged that its acquisition of Community Health Computing in 1995 may have been one of those
LabStat costs sank Community Health Computing
It's not very often that ADAC Laboratories makes a misstep, but this month the Milpitas, CA, company acknowledged that its acquisition of Community Health Computing in 1995 may have been one of those occasions. ADAC on Feb. 11 announced that it was discontinuing development of its LabStat laboratory information system, a product line that ADAC acquired with the CHC purchase.
ADAC said it was shutting down the LabStat project due to high development costs associated with the product line. ADAC also reported that it would discontinue its efforts in digital subtraction angiography, a peripheral business for the company. ADAC will take one-time charges in its first fiscal quarter of 1998 (end-December) of $12.9 million related to LabStat and $3.5 million related to the DSA business.
ADAC acquired CHC in April 1995, five months after the Dallas company entered Chapter 11 bankruptcy proceedings (SCAN 5/10/95). One of the factors leading to CHC's bankruptcy had been the time and money the company was spending on the development of LabStat, an LIS product based on client-server architecture.
When it bought CHC, ADAC saw LabStat as an opportunity to enter the LIS business as a complement to its existing operations in the radiology information systems market. ADAC originally planned to complete LabStat development by 1996, but in the end the company proved no more successful than CHC in finalizing the product. ADAC chairman David Lowe said his company was close to finishing work on LabStat, but decided that the additional expense of the project was not worth the potential returns the product would generate.
"We don't believe that the continued cost of completing the development and the upside from doing so was worth the drag on earnings," Lowe said. "We saw a light at the end of the tunnel, but getting there wasn't worth the cost it would take."
ADAC will continue to support the installed base of its LIS customers, which number between 40 and 50, but does not plan to enter the market for new LIS products, Lowe said. ADAC will continue to market RIS products, which have been selling briskly, and will keep its ADAC HealthCare Information Systems business based in Houston.
The discontinuation of the DSA business completes ADAC's exit from that market, a process that has been going on for several years. ADAC was active in DSA in the 1980s, but since then has focused more on nuclear medicine and information systems. ADAC sold only one or two DSA systems in 1997, Lowe said.
What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound
April 4th 2025In a study recently presented at the American College of Cardiology (ACC) conference, researchers found that novice use of AI-guided cardiac ultrasound after an AI-enabled electrocardiogram increased the positive predictive value for reduced left ventricular ejection fraction (LVEF) or aortic valve stenosis by 33 percent.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.